---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-072304"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T23:18:29.905828+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma shareholders approve equity plan amendment increasing shares by 1M

## Summary
- Stockholders approved amendment to Global Equity Incentive Plan (2021) adding 1,000,000 shares and annual evergreen from 2024-2033.
- Ron Bentsur re-elected as Class I director with 9,035,321 votes for, 149,868 withheld, and 3,284,985 broker non-votes.
- Ratification of Kesselman & Kesselman as independent auditor for FY 2023 approved with 12,468,118 for, 616 against, 1 abstention.

## SEC filing metadata
- accession: 0001104659-23-072304
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/tm2318992d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-072304
- JSON: https://secwatch.observer/filing/0001104659-23-072304.json
- Plain text: https://secwatch.observer/filing/0001104659-23-072304.txt

## Key facts
- Shareholder Votes
  Nuvectis Pharma, Inc. shareholders approved Approval of amendment to Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) at the 2023-06-16 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: The vote with respect to the approval of an amendment to the Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 8,984,698 198,029 2,462 3,284,985
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm
- Shareholder Votes
  Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm at the 2023-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 12,468,118 616 1,440 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm
- Shareholder Votes
  Nuvectis Pharma, Inc. shareholders approved Election of Class I director at the 2023-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: The votes with respect to the election of the Class I director to hold office until the 2026 annual meeting were as follows: Director Votes For Votes Withheld Broker Non-Votes Ron Bentsur 9,035,321 149,868 3,284,985
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.